Market Place
Sourcing Support
Appendix 4C Quarterly Report for Q3 Ended Sept 30, 2024
30 Oct 2024 //
GLOBENEWSWIRE
Depixus Unveils MAGNA One For Biomolecular Interactions
30 Sep 2024 //
BUSINESSWIRE
Mesoblast Option For US$50 Million Convertible Notes for Launch
29 Sep 2024 //
GLOBENEWSWIRE
Mesoblast Reports Financial Results For Fiscal Year Ended June 30, 2024
28 Aug 2024 //
GLOBENEWSWIRE
Mesoblast Financial Results and Corporate Update Webcast
27 Aug 2024 //
GLOBENEWSWIRE
FDA Accepts Mesoblast`s BLA For Ryoncil In Steroid-Refractory aGVHD
23 Jul 2024 //
GLOBENEWSWIRE
Phase 3 Trial Of Rexlemestrocel-L For Chronic Low Back Pain Begins
21 Jul 2024 //
GLOBENEWSWIRE
Mesoblast Resubmits Biologics License Application
09 Jul 2024 //
BIOSPACE
Mesoblast to File BLA for Ryoncil® FDA Approval Next Week
01 Jul 2024 //
GLOBENEWSWIRE
Mesoblast Corporate Presentation At Investor Conference
02 Jun 2024 //
GLOBENEWSWIRE
Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2024
29 Apr 2024 //
GLOBENEWSWIRE
FDA Notifies Mesoblast Available Data from Ph 3 Tria BLA Sub for Remestemcel-L
25 Mar 2024 //
GLOBENEWSWIRE
Mesoblast Successfully Completes Placement and Accelerated Entitlement Offer
13 Mar 2024 //
GLOBENEWSWIRE
Mesoblast Reports Financial Results for Half-Year Ended December 31, 2023
28 Feb 2024 //
GLOBENEWSWIRE
FDA Grants Mesoblast Orphan-Drug Designation for Revascor
14 Feb 2024 //
GLOBENEWSWIRE
Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2023
30 Jan 2024 //
GLOBENEWSWIRE
FDA Grants Mesoblast Rare Pediatric Disease Designation for Revascor
18 Jan 2024 //
GLOBENEWSWIRE
Mesoblast Files for Pediatric Rare Disease Designations for Rexlemestrocel-L
26 Nov 2023 //
GLOBENEWSWIRE
Mesoblast Partners With Blood and Marrow Transplant Clinical Trials Network
21 Nov 2023 //
GLOBENEWSWIRE
Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2023
30 Oct 2023 //
GLOBENEWSWIRE
Mesoblast plots path to market for twice-rejected cell therapy
22 Sep 2023 //
FIERCE BIOTECH
Mesoblast Next Steps to Achieve RYONCIL Approval
21 Sep 2023 //
GLOBENEWSWIRE
Mesoblast ReportsFYR and Operational Update for Fiscal Year Ended June 30, 2023
30 Aug 2023 //
GLOBENEWSWIRE
Mesoblast CEO takes 30% pay cut to fund 3rd shot at FDA approval
30 Aug 2023 //
FIERCE BIOTECH
Mesoblast Financial Results and Corporate Update Webcast
29 Aug 2023 //
GLOBENEWSWIRE
FDA rejects Mesoblast`s cell therapy for bone marrow transplant complications
04 Aug 2023 //
GLOBENEWSWIRE
Appendix 4C Quarterly Activity Report for Quarter Ended June 30, 2023
30 Jul 2023 //
GLOBENEWSWIRE
Mesoblast Director Philip R. Krause, M.D., Appointed to Strategic Advisory Role
04 Jun 2023 //
GLOBENEWSWIRE
Mesoblast Reports Financial Highlights for Quarter Ended March 31, 2023
25 May 2023 //
GLOBENEWSWIRE
Mesoblast Financial Results and Corporate Update Webcast
24 May 2023 //
GLOBENEWSWIRE
Mesoblast Completes Private Placement
25 Apr 2023 //
GLOBENEWSWIRE
FDA Schedules Pre-License Inspection of Remestemcel-L Manufacturing
21 Mar 2023 //
GLOBENEWSWIRE
Mesoblast soars on U.S. FDA`s nod to review lead drug candidate
08 Mar 2023 //
REUTERS
FDA Accepts Mesoblast`s Resubmission of the BLA for Remestemcel-L
07 Mar 2023 //
GLOBENEWSWIRE
DREAM-HF PIII Results for Mesoblast Cell Therapy in Heart Failure Published
27 Feb 2023 //
GLOBENEWSWIRE
Mesoblast Reports Financial Highlights for Quarter Ended December 31
27 Feb 2023 //
GLOBENEWSWIRE
Remestemcel-L Clinical and Potency Studies Presented at Premier Meeting
16 Feb 2023 //
GLOBENEWSWIRE
FDA Grants Rmat Designation for Rexlemestrocel-L in Chronic Low Back Pain
08 Feb 2023 //
GLOBENEWSWIRE
Mesoblast gives cell therapy a 2nd try with FDA—but no new trial
02 Feb 2023 //
FIERCE BIOTECH
Appendix 4C Quarterly Activity Report
31 Jan 2023 //
GLOBENEWSWIRE
Mesoblast Resubmits BLA to FDA for Remestemcel-L in Children With Sr-aGVHD
31 Jan 2023 //
GLOBENEWSWIRE
Mesoblast and Oaktree Extend Availability Period of Undrawn Tranches
22 Dec 2022 //
GLOBENEWSWIRE
Mesoblast sees cell therapy survival data as key to resubmission
23 Nov 2022 //
FIERCEBIOTECH
Mesoblast Reports Financial Results for the Period Ended September 30, 2022
22 Nov 2022 //
GLOBENEWSWIRE
Mesoblast keeps hopes of cell therapy approval alive
03 Oct 2022 //
FIERCEBIOTECH
Mesoblast Submits New Information to FDA IND for SR-aGVHD
02 Oct 2022 //
GLOBENEWSWIRE
Mesoblast Reports Financial Results and Operational Highlights forFY Ended
30 Aug 2022 //
GLOBENEWSWIRE
Jane Bell Joins Mesoblast Board
18 Aug 2022 //
GLOBENEWSWIRE
Rexlemestrocel-L to be Highlighted at Maxim`s Panel on Late-Stage Advancements
11 Jul 2022 //
GLOBENEWSWIRE
Mesoblast Key Opinion Leader Event Series for Investors & Analysts
09 Jun 2022 //
GLOBENEWSWIRE
Philip R. Krause, Former FDA Deputy Chief for Vaccines, Joins Mesoblast Board
23 Mar 2022 //
GLOBENEWSWIRE
Mesoblast Corporate Update and Financial Results Webcast
24 Feb 2022 //
GLOBENEWSWIRE
Rapid Improvement, Remission in Refractory Ulcerative Colitis & Crohn’s Colitis
20 Feb 2022 //
GLOBENEWSWIRE
Mesoblast Appoints Dr. Eric Rose as Chief Medical Officer
01 Feb 2022 //
GLOBENEWSWIRE
Appendix 4C Quarterly Activity Report
30 Jan 2022 //
GLOBENEWSWIRE
Single Dose of Mesoblast Allogeneic Cell Therapy Provides Durable Pain Reduction
11 Jan 2022 //
GLOBENEWSWIRE
Mesoblast Provides Update Following Meeting With FDA’s OTAT on Remestemcel-L
30 Dec 2021 //
GLOBENEWSWIRE
Mesoblast shares depressed by Novartis deal termination
15 Dec 2021 //
BIOWORLD
Novartis Drops Out of COVID-19 Deal with Mesoblast
15 Dec 2021 //
BIOSPACE
Mesoblast and Oaktree Capital Enter Into Refinancing and Expansion
20 Nov 2021 //
GLOBENEWSWIRE
